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ABSTRACT
Chikungunya virus (CHIKV) is a mosquito-borne pathogen that causes an acute febrile syndrome and severe, debilitating
rheumatic disorders in humans that may persist for months. CHIKV’s presence in Asia dates from at least 1954, but its
epidemiological proﬁle in the region remains poorly understood. We systematically reviewed CHIKV emergence,
epidemiology, clinical features, atypical manifestations and distribution of virus genotypes, in 47 countries from South
East Asia (SEA) and the Western Paciﬁc Region (WPR) during the period 1954–2017. Following the Cochrane
Collaboration guidelines, Pubmed and Scopus databases, surveillance reports available in the World Health
Organisation (WHO) and government websites were systematically reviewed. Of the 3504 records identiﬁed, 461 were
retained for data extraction. Although CHIKV has been circulating in Asia almost continuously since the 1950s, it has
signiﬁcantly expanded its geographic reach in the region from 2005 onwards. Most reports identiﬁed in the review
originated from India. Although all ages and both sexes can be aﬀected, younger children and the elderly are more
prone to severe and occasionally fatal forms of the disease, with child fatalities recorded since 1963 from India. The
most frequent clinical features identiﬁed were arthralgia, rash, fever and headache. Both the Asian and East-Central-
South African (ECSA) genotypes circulate in SEA and WPR, with ECSA genotype now predominant. Our ﬁndings
indicate a substantial but poorly documented burden of CHIKV infection in the Asia-Paciﬁc region. An evidence-based
consensus on typical clinical features of chikungunya could aid in enhanced diagnosis and improved surveillance of
the disease.
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Introduction
Chikungunya, a re-emerging tropical disease with a
widespread geographical distribution [1], is caused by
chikungunya virus (CHIKV), an alphavirus of the
family Togaviridae. The virus is transmitted between
humans through the bite of an infected Aedes mos-
quito, primarily Ae. aegypti or Ae. albopictus. Chikun-
gunya is generally self-limiting, with patients
experiencing high fevers, headache, nausea/vomiting,
persistent and sometimes debilitating myalgia/arthral-
gia, and maculopapular rash [2,3]. It can lead to pro-
longed arthralgia, lasting for several months and
severely reduce the quality of life in patients [4].
Although chikungunya is rarely fatal, the virus can be
a signiﬁcant cause of central nervous system disease
in the context of a large outbreak, placing younger chil-
dren and elderly with co-morbidities at risk [5,6].
Three major CHIKV genotypes have been ident-
iﬁed: West African, East/Central/South African
(ECSA) and Asian [7]. Since CHIKV’s ﬁrst description
in 1952 in Tanzania [3], intermittent outbreaks have
been recorded in Africa, Asia, and the Indian Ocean
Islands [8–10]. In 2004, a major epidemic started in
eastern Kenya [11], spread to several Indian Ocean
Islands, India, and South East Asia (SEA) [12,13] and
severely aﬀected La Reunion (2005–2006) [14]. The
epidemic saw the development of clinical compli-
cations not previously associated with CHIKV [14],
and adaptation of an ECSA strain (the Indian Ocean
Lineage, or IOL) to Ae. albopictus vectors, resulting
in enhanced transmission rates [15,16]. The adaptation
has possibly facilitated worldwide epidemics and out-
breaks over the past decade in Asia, the Indian subcon-
tinent and Europe [17–19]. In 2013, CHIKV emerged
in the Western Hemisphere, and since then, 46
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countries from the Americas have reported local trans-
mission, with over 1.7 million suspected cases [20].
CHIKV continues to cause outbreaks globally [21],
and it is estimated that 39% of the world’s population
lives in areas endemic for the virus [22]. Infections
can result in signiﬁcant morbidity due to the acute
and chronic disability associated with the disease
[23], placing a heavy burden on health systems and
infrastructure, and resulting in signiﬁcant socio-econ-
omic consequences to individuals [24,25]. Despite the
large burden of disease and the almost continuous cir-
culation of CHIKV in Asia since the early 1950s, the
epidemiological proﬁle of the virus remains poorly
characterized for SEA and the Western Paciﬁc Region
(WPR). We systematically reviewed available records
documenting CHIKV circulation in the countries of
SEA and the WPR over the past 70 years, with empha-
sis on epidemiological history, clinical features, and
distribution of virus genotypes. This knowledge will
aid the development of strategies to detect, prevent
and respond to future outbreaks, identifying at-risk
populations, enhancing accurate diagnosis, and
improving treatment eﬀorts.
Results
The selection process initially identiﬁed a total of 3504
records, from which 905 duplicates were removed
(Figure 1). Among the remaining 2599 records, 2051
were excluded during the screening of abstracts as
they did not meet the eligibility criteria. The full texts
of the remaining 548 records were then assessed for eli-
gibility. Following full-text review, 87 records were
excluded according to criteria given in Figure 1. There-
fore, a total of 461 records were considered for further
analysis (see appendix pp. 1–15, Supplementary Table
1). Within these 461 records, 79 WPR syndromic sur-
veillance reports were considered only for descriptions
of place and time, but not for descriptions of other out-
comes as many did not clearly describe laboratory
conﬁrmation of the cases.
Epidemiology and chronology of CHIKV
Records were classiﬁed according to the type of CHIKV
event: 23 records described epidemics, 165 described
outbreaks, 18 had inconclusive categorization as either
epidemic or outbreak, 31 reported imported cases, 9
reported disease clusters/case series, and 12 reported
sporadic cases (Figure 2). A ﬁnal category of 203 mis-
cellaneous records included 149 surveillance/serologi-
cal surveys/seroprevalence studies, 47 records on
atypical manifestations, and 7 other records that
could not be classiﬁed into any of the above categories.
The person, place, and time of these records are
described below.
Person
There were 52 records describing the age and sex of per-
sons aﬀected by CHIKV (see appendix pp 1–15, Sup-
plementary Table 1). Twelve records indicated that
CHIKV solely aﬀected adults and four records presented
evidence of infection in both adults and adolescents.
However, most studies (36/52) indicated that all age
groups were aﬀected. Among these, the highest number
(11/36) indicated that patients 20–40 years old were the
most aﬀected, followed by people 40–60 years old (8/36).
Only one study indicated that children aged 4–5 years
old (reference 50, see appendix pp 41 for References)
weremost frequently aﬀected, whereas two records indi-
cated that people older than 60 years of agewere aﬀected.
The latter two records describedoutbreaks inMaharash-
tra, India from January to December 2006, and in
Guangdong province of China from September toOcto-
ber 2010. A further two records of an outbreak (Karna-
taka, India) at two diﬀerent times (January to Sept 2008
and June 2008 to May 2009) indicated that people over
45 years of age were aﬀected most frequently. However,
a third of records (12/36) reported variable ages for per-
sons aﬀected by CHIKV. Almost 35% of records indi-
cated that males were aﬀected more than females,
while another 32% indicated female predominance. A
similar proportion (30%) of records indicated that
both sexes were equally aﬀected, with another 3% pre-
senting no information. Overall, the evidence indicated
both sexes suﬀer equal burdens of the disease.
Place of occurrence
The records indicated that CHIKV has steadily
expanded its range in the Asia-Paciﬁc over the last 70
years (Figure 3). India (174 records, 46%), Thailand
(35 records, 9%), and Malaysia (26 records, 6.81%)
have reported CHIKV circulation since the virus was
ﬁrst reported to have reached SEA prior to 1960 (see
appendix pp 16, Supplementary Table 2) [26]. The
SEA region accounted for 67.02% of records, and
CHIKV epidemics were reported only from India, Thai-
land, and Sri Lanka. The WPR syndromic surveillance
records were considered separately from the above, as
they reportmultiple countries in the same report. Amer-
ican Samoa, Cook Islands, Marshall Islands, Kiribati,
Nauru, Samoa, Tokelau, Tonga, and Tuvalu also
reportedCHIKVactivity. However, information on lab-
oratory conﬁrmation ofCHIKVcaseswas only available
for some outbreaks. Only imported CHIKV cases were
reported from Niue, Hong Kong, Korea, Japan, Cook
Islands, New Zealand, and Australia.
Time of occurrence
Prior to 2000, most records dated from the period
1961–1970. The two decades following the year 2000
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accounted for nearly 83% of records identiﬁed (see
appendix pp 17, Supplementary Table 3). From the
1950s to 2017, CHIKV outbreaks and/or epidemics
most frequently occurred in India, Indonesia,
Thailand, and Philippines (Figure 4). A retrospective
analysis of human sera indicated that CHIKV was cir-
culating in the SEA region in 1954. The ﬁrst epidemic
co-infection of CHIKV with dengue virus was detected
Figure 1. Flow chart of record selection for inclusion in the systematic review.
Figure 2. Distribution and number of records according to the type of CHIKV activity. The miscellaneous category includes surveil-
lance/serological surveys/seroprevalence studies, atypical manifestations and other records that cannot be classiﬁed into any of the
other categories.
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in Thailand in 1958. India reported its ﬁrst CHIKV
outbreak in 1963. However, a disease with similar clini-
cal features was ﬁrst noticed in 1779 from Indonesia,
although a number of infectious agents can lead to
similar symptoms [27]. Among WPR countries, Singa-
pore reported the ﬁrst CHIKV activity in 1960 while
Cambodia reported the ﬁrst disease cluster infected
with CHIKV in 1961. Within the Western Paciﬁc
islands, New Caledonia reported its ﬁrst outbreak in
2011. Intervals between CHIKV outbreaks were
observed in Sri Lanka (41 years), India (32 years), Phi-
lippines (28 years: 1968–1996, 15 years: 1996–2011),
Myanmar (14 years), Thailand (13 years), Malaysia (7
years), and Indonesia (6–8 years) (see appendix pp
Figure 3. Spatial-temporal expansion of CHIKV in SEA and the WPR regions, including records of both local and imported cases.
Figure 4. Heat map of CHIKV outbreaks and epidemics in the countries of SEA and the WPR regions, by year (1963-2017).
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17 for Supplementary Table 3). The majority of
countries in SEA and the WPR have experienced
CHIKV outbreaks and/or epidemics only since the
mid-2000s (Figure 4).
Attack rate
The attack rate during speciﬁc CHIKV outbreaks and
epidemics was described in 22 records (see appendix
pp 18-19, Supplementary Table 4). The clinical attack
rate was based on clinical symptoms, whereas the lab-
oratory-conﬁrmed attack rate used the number of lab-
oratory-conﬁrmed CHIKV cases. The clinical attack
rates of speciﬁc outbreaks ranged from 0.28% to
73.4% in Indonesia in 2001 and Cambodia in 2012,
respectively. The laboratory-conﬁrmed attack rate ran-
ged from 0.13% to 58.3%. Both minimum and maxi-
mum laboratory-conﬁrmed attack rates were reported
in India in 2010 and 2008, respectively. Other high
CHIKV attack rates were 55.6% and 44.7%, reported
from Malaysia (2007) and Cambodia (2012)
respectively.
Clinical features of CHIKV infection and atypical
manifestations including rare complications
Among the records reporting clinical features associ-
ated with CHIKV infection, we only considered the
64 records where all cases described had been labora-
tory-conﬁrmed (see appendix pp 20–22, Supplemen-
tary Table 5). The most commonly reported clinical
features were arthralgia, rash, fever, and headache, as
they were recorded in at least 50% of studies
(Table 1). Chikungunya infection can lead to a broad
spectrum of neurological disorders, as well as ocular,
cardiovascular, respiratory, skin, auditory, oral, and
musculoskeletal manifestations (see appendix pp 23,
Supplementary Table 6). Atypical manifestations
associated with CHIKV infection begin to be reported
only in 2008. There were 47 records on atypical mani-
festations, of which nearly 38.3% (18 records) were
related to neurological disorders (see appendix pp 23,
Supplementary Table 6). The second most common
was cardiovascular manifestations, at 19.1% (9
records). Additional atypical manifestations were rare
dermatologic manifestations, oral candidiasis, hypoka-
laemic paralysis, and autoimmune polymyositis. Rare
complications following CHIKV infection included
thrombotic thrombocytopenic purpura, atypical Kawa-
saki disease, leukemoid reaction, acute auditory neuro-
pathy spectrum disorder, and sudden sensorineural
hearing loss with acute respiratory distress syndrome.
Death due to CHIKV
There were 12 records, predominantly reported from
India and Malaysia, describing 48 cases of death due
to (laboratory-conﬁrmed) infection with CHIKV (see
appendix pp 24, Supplementary Table 7). Of these
cases, 10% were less than 20 years of age, 20% were
20–60 years and 60% were over 60 years of age. India
reported the ﬁrst death due to CHIKV in 1963, and
thereafter in 1964, 2006, 2007, and 2011. The most
recent reported death attributable to CHIKV infection
involved a 12-year old boy from Bangalore, India
(2015). Fatalities due to CHIKV infection were also
reported from Malaysia in 2008 and 2010 and from
Niue in 2015. Fatalities occurred in patients both lack-
ing and with co-morbidities such as hypertension,
ischemic heart disease, and diabetes mellitus.
Vertical transmission
There were 11 records on vertical transmission of
CHIKV from mother to neonate during 2008–2016.
Nine records were from India and one each from Sri
Lanka and Thailand (see appendix pp 25, Supplemen-
tary Table 8). The infants showed a spectrum of
cutaneous manifestations, however, in some cases, sys-
temic manifestations were also apparent. Mothers were
viremic at the time of delivery in all vertically trans-
mitted cases that resulted in serious consequences to
the baby.
CHIKV genotype distribution
A total of 95 records reported the genotype of CHIKV
circulating in SEA and the WPR (see appendix, pp 26–
29, Supplementary Table 9). In the majority (62.1%) of
records, CHIKV genotype was determined based on E1
gene sequencing (partial or complete) (see appendix, p
Table 1. Most commonly reported clinical features of CHIKV
infection.
Clinical feature (total number of records
= 64)
No. of
records
Percentage
(%)
Arthralgia 40 62.5
Rash 36 56.3
Fever 35 54.7
Headache 33 51.6
Myalgia 30 46.9
Vomiting 21 32.8
Arthritis 17 26.6
Diarrhoea 14 21.9
Shivering/chills or rigour 13 20.3
Cough 12 18.8
Abdominal pain 10 15.6
Nausea 10 15.6
Conjunctival infection 9 14.1
Lymphadenopathy 8 12.5
Haemorrhage 8 12.5
Sore throat 7 10.9
Eye pain 6 9.4
Pruritis/ itching 6 9.4
Liver involvement 5 7.8
Oral ulcer/gingivitis 5 7.8
Bleeding gums 5 7.8
Back pain 5 7.8
Anorexia 5 7.8
Notes: Percentage = (Number of records reporting the ﬁnding/total num-
ber of records64) × 100. Refer to Supplementary Table 8 for references.
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30, Supplementary Table 10). Thailand, India, Indone-
sia, Malaysia, and Philippines reported sporadic cases
and outbreaks of Asian genotype CHIKV during
1950s to 2005, when ECSA strains appear in the region
for the ﬁrst time (Figure 5). Since then, outbreaks
involving ECSA strains have occurred almost every
year. The ﬁrst reports of ECSA-IOL strains were
made in 2007 from India and Thailand. The majority
(80%) of reports concerned strains of ECSA genotype,
including 35% of reports documenting IOL strains.
Some countries only reported the presence of strains
from ECSA genotype (Bhutan, Myanmar, and Viet-
nam), whereas others only the presence of Asian geno-
type (New Caledonia and French Polynesia) (Figure 5).
Several countries, including Indonesia, Thailand, and
Malaysia, experienced circulation of both genotypes.
At the time of the review, among countries with only
imported cases, Australia and South Korea had
reported only ECSA genotype and Japan both geno-
types. In India, ECSA-IOL strains were only reported
during 2007–2010, while strains reported more
recently from 2011–2014 belonged to the ECSA geno-
type but not to this lineage (see appendix pp 26–29,
Supplementary Table 9).
Discussion
Our ﬁndings show that CHIKV has circulated in the
Asia-Paciﬁc region since the 1950s, causing sporadic
outbreaks in SEA almost every decade from the
1960s. CHIKV activity has steadily expanded since
the 1960s, reaching the Western Paciﬁc islands in
2011. Although the ﬁrst evidence of human CHIKV
infection in SEA was obtained from sera collected in
India in 1954 [28], the ﬁrst laboratory-conﬁrmed out-
break occurred in Thailand in the form of an epidemic
with dengue co-infection in 1958 [26]. Large CHIKV
outbreaks then occurred in SEA between 1961 and
1970 and by 2011, the virus had spread to the countries
of Western Paciﬁc islands. Many countries in the SEA
region have experienced re-emergence of the disease in
recent decades. Unlike a previous report [29], we found
intervals between outbreaks in the same country ran-
ged from 6 (Indonesia) to 41 (Sri Lanka) years. It is
likely that our review identiﬁed earlier reports that
had not been previously available. The widely varying
intervals observed suggest that improving prediction
of CHIKV outbreaks and epidemics will remain
challenging.
Our results suggest that India has experienced the
highest burden of CHIKV in the Asia-Paciﬁc region.
Circulation of CHIKV in India seems to have been
almost continuous since the ﬁrst incursion of the
virus into SEA, with the greatest number of reports
originating in that country. The highest attack rate
for CHIKV in India thus far indicated by WHO is
45% [30], but our data suggests it can reach 58.3%
(India, 2008) for laboratory-conﬁrmed cases. Despite
the perception that CHIKV-associated mortality was
ﬁrst observed in La Reunion in 2005–2006 [31], we
found evidence for fatalities occurring since the ﬁrst
reported outbreak in 1963 in India.
In agreement with previous observations [32], our
study conﬁrms that CHIKV causes more severe disease
and can be fatal in children and the elderly (>60 years
old), even in the absence of co-morbidities, whereas
Figure 5. Spatial-temporal distribution of CHIKV genotypes. There was no sequencing information reported for the period 2015–
2017 over the period considered for the review.
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healthy adults usually experience only self-limiting
infections. Though the number of fatal cases identiﬁed
during our review is relatively small, this may be an
underestimate given that conﬁrmatory diagnosis is
often not performed due to resource limitations
[2,33–36] and CHIKV may be mistaken for dengue
[1,27,37].
We found that chikungunya can aﬀect all ages but
most commonly aﬀects people of 20–60 years old, of
either sex. The disease has a broad spectrum of clinical
manifestations, with almost all body systems aﬀected.
There is a lack of consensus on the common clinical
features of CHIKV, as evidenced by diﬀerent guidelines
oﬀered by various health authorities. For example, typi-
cal symptoms identiﬁed by the WHO Guidelines on
Clinical Management of Chikungunya Fever (2008)
include fever, arthralgia, back ache, and headache,
while the US Centres for Disease Control (CDC) indi-
cate only fever and polyarthralgia [38,39]. Our review
failed to identify back pain as a commonly reported
feature, with just over 7.8% of reports identifying it
as a symptom. Our ﬁndings are similar to those of
Zim et al. [40], who also concluded that arthralgia
and rash were commonly associated with CHIKV.
While WHO guidelines list rash as an infrequent
symptom, we found that rash and headache were
reported almost as frequently as fever. According to
the aforesaid WHO guidelines, retro-orbital pain,
vomiting, and diarrhoea are rarely observed in adults
(although occasionally seen in children), yet our results
indicate otherwise. An evidence-based consensus on
the typical clinical features of chikungunya may aid
in improving diagnosis and management of the disease.
Instances of vertical transmission were found to be
relatively rare given the large number of CHIKV
cases reported during outbreaks in SEA and the
WPR. A comprehensive study conducted during the
La Reunion outbreak in 2005–2006 identiﬁed possible
vertical (mother-to-child) transmission of CHIKV
from mother to neonate when the mother had viremia
at the time of delivery [41]. Similarly, our review ident-
iﬁed the instance of vertical transmission of CHIKV
from mother to the neonate, with most reports orig-
inating from cases in India. CHIKV infection and
serious consequences were found in infants who had
contracted CHIKV from viremic mothers during deliv-
ery, such as neurological or haematological features
that can establish permanent disability in the infant
[42]. A recent review of CHIKV vertical transmission
cases worldwide identiﬁed that long-term neurodeve-
lopmental delays occurred in 50% of neonatal infec-
tions that showed clinical symptoms [43].
A large proportion of outbreaks in SEA and WPR
recorded since 2005 have involved CHIKV strains of
the ECSA genotype. Interestingly, in India, we found
the predominance of the IOL lineage has declined
from a peak during 2007–2011 and may have been
displaced by other ECSA strains in recent years. The
Asian genotype continues to circulate in SEA and the
WPR regions. Following the end date of this systematic
review (09/2017), Pyke et al. (2018) reported a case of
Asian genotype CHIKV imported into Australia from
the Philippines in 2016, indicating recent circulation
of the Asian genotype [44]. Press reports from the Phi-
lippines during this period indicate a chikungunya out-
break, with over 400 cases [45]. It is clear that the ECSA
genotype, including the IOL lineage, has not displaced
Asian strains in these regions since 2005, and that both
genotypes present an export risk to other areas with
suitable vectors.
There are several limitations to this systematic
review. First, there is no proper classiﬁcation or deli-
neation of CHIKV outbreaks and epidemics, possibly
due to a lack of consensus on deﬁnitions for CHIKV
in general [46]. As CHIKV infections can be misdiag-
nosed/misinterpreted for dengue [27,37,47] virus
occurrence and burden of disease in these regions are
likely grossly underestimated. A second limitation
relates to the quality of information and the frequent
absence of laboratory conﬁrmation of cases and out-
breaks. Many of the SEA and WPR countries do not
have surveillance systems for CHIKV, possibly due to
resource constraints. Therefore, under-reporting and
small number of studies on CHIKV epidemiology
and clinical manifestations are pervasive problems.
Elucidating the epidemiology, circulation and clini-
cal manifestations of CHIKV in the Asia-Paciﬁc is criti-
cal to understanding the potential for virus re-
emergence. Our ﬁndings could improve the accuracy
of diagnosis and surveillance, which may assist in the
management and prevention of future outbreaks in
the region.
Methods
Search strategy and selection criteria
The systematic review was performed according to the
Cochrane Collaboration guidelines [48], and ﬁndings
compiled following the “Preferred Reporting Items
for Systematic Reviews and Meta-analyses” (PRISMA)
format [49]. The term “record” refers to any retrieved
document that contains an outcome measure such as
epidemiological history, clinical features, and distri-
bution of virus genotypes. The report type, study
design, and outcomes reported in each record were sys-
tematically screened for inclusion or exclusion in the
review, based on predeﬁned eligibility criteria (see
appendix pp 31, Supplementary Table 11). All records
containing serological surveys, imported cases, spora-
dic cases, case series, disease clusters, outbreaks and
epidemics that reported CHIKV incidence (conﬁrmed
by any laboratory method), over any time interval and
in human populations were considered for inclusion in
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this study. Epidemics, outbreaks, and disease clusters
were categorized as such based on the classiﬁcation
used by the original authors [46]. CHIKV outbreaks
and epidemics were considered eligible for inclusion
if at least a subset of cases was laboratory-conﬁrmed.
Demography, clinical features, atypical ﬁndings includ-
ing rare complications and vertical transmission were
described only using the cases with clear laboratory
conﬁrmation. This systematic review covers 47
countries in SEA and the WPR as deﬁned on the
26th of July 2017 (see appendix p 32 for the country
list – Supplementary Table 12, and pp 33–38 for full
search strategy – Supplementary Table 13). PubMed
and Scopus databases, World Health Organisation
Western Paciﬁc syndromic surveillance reports were
searched by using the keywords: “chikungunya” and
“country.” The search was conducted from 26th July
2017 and updated on 17th September 2018. Bibliogra-
phies of records identiﬁed through these searches were
further examined for publications that were not cap-
tured in the primary database searches. The biblio-
graphic information was used to extract information
from Promed reports (http://www.promedmail.org/)
and web databases of the respective governments.
Data analysis
Records were imported into Endnote X8 bibliographic
software (X8.0.1; Thompson Reuters, Philadelphia,
USA) and an Excel (Microsoft) ﬁle. Duplicate publi-
cations were removed, and records containing the
same research data/ﬁndings published by the same
author in diﬀerent formats/titles were counted only
once. Retrieved titles and abstracts, and then poten-
tially eligible full-text records, were screened indepen-
dently by two reviewers based on the predeﬁned
inclusion and exclusion criteria (see appendix p 31
for Supplementary Table 11). Records required an
abstract in the English language to be included. Ineligi-
ble records were excluded from analyses, and eligible
reports were used for data extraction. The following
data were extracted and recorded in tables: the type
of occurrence (surveillance/serological survey,
imported case, case study, sporadic case, case series,
disease cluster, outbreak, or epidemic), demography
(age and sex), year, and place. Clinical features along
with atypical clinical manifestations were only
recorded for laboratory-conﬁrmed CHIKV cases. Aty-
pical manifestations were deﬁned as features speciﬁc to
particular organ systems that were relatively uncom-
mon [42]. Vertical transmission, attack rates and
deaths due to CHIKV were reported separately. The
viral genotype was recorded according to the year,
month, country, and city from where it was reported.
Basic descriptive analysis was performed using
GraphPad Prism version 7 (GraphPad Software, La
Jolla, California, USA). Maps were produced using
ArcGIS version 10.6 (ESRI Inc., Redlands, California,
USA). Heat maps to display numbers of records avail-
able for each country across the decades were produced
using the R package heatmap version 3.3 (R Foun-
dation for Statistical Computing, Vienna, Austria).
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